Pliant Sees Treating Fibrosis As Primary Goal, Not Add-On
This article was originally published in The Pink Sheet Daily
Start-up will advance UCSF research on fibrosis to improve upon current treatments for idiopathic pulmonary fibrosis, and possibly create therapeutics for fibrosis of the liver, kidneys and GI tract as well.
You may also be interested in...
FDA leaders explain in NEJM how they came to accept a measure of lung function as a surrogate for mortality in trials of idiopathic pulmonary fibrosis therapies. See how agency reviewers handled this in a preview of our upcoming Drug Review Profile series.
Court finds US FDA did not impede Catalyst orphan exclusivity for Firdapse as it approved different indication for competing product. Biogen loses 10-year patent battle against competing multiple sclerosis drug makers.
Cover Three Nutritional Brain Defense marketer agrees to pull claims suggesting the supplement beverage can protect against traumatic brain injury after a test the firm on DHA submitted as support contained considerably higher levels of the ingredient than included in the product.